These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25077772)

  • 21. An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.
    Tomoshige K; Guo M; Tsuchiya T; Fukazawa T; Fink-Baldauf IM; Stuart WD; Naomoto Y; Nagayasu T; Maeda Y
    Oncogene; 2018 Jul; 37(28):3894-3908. PubMed ID: 29662194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Evidence for XPC-KRAS Interactions During Lung Cancer Development.
    Zhang X; He N; Gu D; Wickliffe J; Salazar J; Boldogh I; Xie J
    J Genet Genomics; 2015 Oct; 42(10):589-596. PubMed ID: 26554912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL22 Promotes
    Khosravi N; Caetano MS; Cumpian AM; Unver N; De la Garza Ramos C; Noble O; Daliri S; Hernandez BJ; Gutierrez BA; Evans SE; Hanash S; Alekseev AM; Yang Y; Chang SH; Nurieva R; Kadara H; Chen J; Ostrin EJ; Moghaddam SJ
    Cancer Immunol Res; 2018 Jul; 6(7):788-797. PubMed ID: 29764837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy.
    Tian D; Tang J; Geng X; Li Q; Wang F; Zhao H; Narla G; Yao X; Zhang Y
    Cancer Lett; 2020 Nov; 493():80-90. PubMed ID: 32814087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of Mutant
    Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
    Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.
    Figueiredo ML; Stein TJ; Jochem A; Sandgren EP
    Liver Int; 2012 Apr; 32(4):582-91. PubMed ID: 22221894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia.
    Kim SY; Johns SC; Gupta P; Varki N; Fuster MM
    Neoplasia; 2021 Nov; 23(11):1137-1143. PubMed ID: 34715561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
    Rangel DF; Dubeau L; Park R; Chan P; Ha DP; Pulido MA; Mullen DJ; Vorobyova I; Zhou B; Borok Z; Offringa IA; Lee AS
    Oncogene; 2021 May; 40(20):3624-3632. PubMed ID: 33931739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer.
    Kim BS; Clinton J; Wang Q; Chang SH
    Oncoimmunology; 2020; 9(1):1682380. PubMed ID: 32002289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
    Tsuchida N; Murugan AK; Grieco M
    Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors.
    Manenti G; Trincucci G; Pettinicchio A; Amendola E; Scarfò M; Dragani TA
    Oncogene; 2008 Sep; 27(43):5753-8. PubMed ID: 18560355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
    Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
    Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
    Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
    Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer.
    Fukazawa T; Maeda Y; Matsuoka J; Ono T; Mominoki K; Yamatsuji T; Shigemitsu K; Morita I; Murakami I; Tanaka H; Durbin ML; Naomoto Y
    Anticancer Res; 2010 Dec; 30(12):4925-35. PubMed ID: 21187472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux.
    Wiersma VR; de Bruyn M; Wei Y; van Ginkel RJ; Hirashima M; Niki T; Nishi N; Zhou J; Pouwels SD; Samplonius DF; Nijman HW; Eggleton P; Helfrich W; Bremer E
    Autophagy; 2015; 11(8):1373-88. PubMed ID: 26086204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.